128 related articles for article (PubMed ID: 36579219)
1. Potential Limitations in the Clinical Adoption of 3-GEP Pigmented Lesion Assay for Melanoma Triage by Dermatologists and Advanced Practice Practitioners.
Ludzik J; Lee C; Witkowski A
Cureus; 2022 Nov; 14(11):e31914. PubMed ID: 36579219
[TBL] [Abstract][Full Text] [Related]
2. Dermoscopic features associated with 3-GEP PLA: LINC00518, PRAME, and TERT expression in suspicious pigmented lesions.
Ludzik J; Becker AL; Latour E; Lee C; Witkowski A
Skin Res Technol; 2023 Apr; 29(4):e13323. PubMed ID: 37083005
[TBL] [Abstract][Full Text] [Related]
3. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.
Ferris LK; Jansen B; Ho J; Busam KJ; Gross K; Hansen DD; Alsobrook JP; Yao Z; Peck GL; Gerami P
JAMA Dermatol; 2017 Jul; 153(7):675-680. PubMed ID: 28445578
[TBL] [Abstract][Full Text] [Related]
4. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
Ferris LK; Gerami P; Skelsey MK; Peck G; Hren C; Gorman C; Frumento T; Siegel DM
Melanoma Res; 2018 Oct; 28(5):478-482. PubMed ID: 30004988
[TBL] [Abstract][Full Text] [Related]
5. Non-Invasive Gene Expression Testing to Rule Out Melanoma.
Rivers JK; Copley MR; Svoboda R; Rigel DS
Skin Therapy Lett; 2018 Sep; 23(5):1-4. PubMed ID: 30248161
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma.
Ferris LK; Moy RL; Gerami P; Sligh JE; Jansen B; Yao Z; Cockerell CJ
J Invest Dermatol; 2019 May; 139(5):1127-1134. PubMed ID: 30500343
[TBL] [Abstract][Full Text] [Related]
7. Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions.
Hornberger J; Siegel DM
JAMA Dermatol; 2018 Sep; 154(9):1025-1031. PubMed ID: 29998292
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.
Gerami P; Yao Z; Polsky D; Jansen B; Busam K; Ho J; Martini M; Ferris LK
J Am Acad Dermatol; 2017 Jan; 76(1):114-120.e2. PubMed ID: 27707590
[TBL] [Abstract][Full Text] [Related]
9. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study.
Ferris LK; Rigel DS; Siegel DM; Skelsey MK; Peck GL; Hren C; Gorman C; Frumento T; Jansen B; Yao Z; Rock J; Knezevich SR; Cockerell CJ
Dermatol Online J; 2019 May; 25(5):. PubMed ID: 31220892
[TBL] [Abstract][Full Text] [Related]
10. Analytical Characteristics of a Noninvasive Gene Expression Assay for Pigmented Skin Lesions.
Yao Z; Allen T; Oakley M; Samons C; Garrison D; Jansen B
Assay Drug Dev Technol; 2016 Aug; 14(6):355-63. PubMed ID: 27505074
[TBL] [Abstract][Full Text] [Related]
11. Pigmented Lesion Assay for Suspected Melanoma Lesions: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(5):1-81. PubMed ID: 34188732
[TBL] [Abstract][Full Text] [Related]
12. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
Serban ED; Farnetani F; Pellacani G; Constantin MM
Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
[TBL] [Abstract][Full Text] [Related]
13. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
14. Genomic Evaluation of Clinically Ambiguous Pigmented Lesions.
Ruiz J; Hyde M; Perry A; Brouha B
J Clin Aesthet Dermatol; 2023 Jun; 16(6):44-45. PubMed ID: 37361365
[TBL] [Abstract][Full Text] [Related]
15. Gene Expression Analysis Differentiates Melanomas from Spitz Nevi.
Jansen B; Hansen D; Moy R; Hanhan M; Yao Z
J Drugs Dermatol; 2018 May; 17(5):574-576. PubMed ID: 29742191
[TBL] [Abstract][Full Text] [Related]
16. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
[TBL] [Abstract][Full Text] [Related]
17. Assessment of a Diagnostic Predictive Probability Model Provided by a Multispectral Digital Skin Lesion Analysis Device for Melanoma and Other High-risk Pigmented Lesions and its Impact on Biopsy Decisions.
Winkelmann RR; Yoo J; Tucker N; White R; Rigel DS
J Clin Aesthet Dermatol; 2014 Dec; 7(12):16-8. PubMed ID: 25584133
[TBL] [Abstract][Full Text] [Related]
18. Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists.
Chen SC; Pennie ML; Kolm P; Warshaw EM; Weisberg EL; Brown KM; Ming ME; Weintraub WS
J Gen Intern Med; 2006 Jul; 21(7):678-82. PubMed ID: 16808765
[TBL] [Abstract][Full Text] [Related]
19. Response to Bass et al.'s "Significant discordance in DermTech test results when paired with histopathology: Caveat emptor".
Moncayo AK; Grossman D; Kim CC; Hartman RI
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38852741
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
